Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Journal of Clinical Oncology

• Publication date

  2001-01-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2001.19.2.289PMID 11208818
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Virus Entry into Animal Cells

  2008cited by this paper
• Studies on the biological characteristics of the newcastle disease virus (NDV) adapted to the brain of newborne mice

  2005cited by this paper
• Superinfection of tumors with viruses

  2005cited by this paper
• Adjuvant treatment of locally advanced renal cancer with autologous virus-modified tumor vaccines

  2004cited by this paper
• Ifosfamide in advanced epidermoid head and neck cancer

  2004cited by this paper
• ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients.

  2000cited by this paper
• Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer.

  2000cited by this paper
• Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer.

  1999cited by this paper
• Smallpox: Gone but not forgotten

  1998cited by this paper
• ONYX-015: Clinical data are encouraging

  1998cited by this paper
• Bispecific antibodies increase T-cell stimulatory capacity in vitro of human autologous virus-modified tumor vaccine.

  1998cited by this paper
• Phase III trial of modulation of cisplatin/fluorouracil chemotherapy by interferon alfa-2b in patients with recurrent or metastatic head and neck cancer. Head and Neck Interferon Cooperative Study Group.

  1998cited by this paper
• Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma.

  1998cited by this paper
• Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck

  1998cited by this paper
• p53 Status Does Not Determine Outcome of E1B 55-Kilodalton Mutant Adenovirus Lytic Infection

  1998cited by this paper
• In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity.

  1998cited by this paper
• p53-dependent cell death/apoptosis is required for a productive adenovirus infection

  1998cited by this paper
• Parenteral Gene Therapy with p53 Inhibits Human Breast Tumors In Vivo Through a Bystander Mechanism Without Evidence of Toxicity

  1997cited by this paper
• Phase II study of vinorelbine (NVB) in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck (SCCHN)

  1997cited by this paper
• ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

  1997cited by this paper
• A phase II study of topotecan in patients with recurrent head and neck cancer. Identification of an active new agent.

  1997cited by this paper
• Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts.

  1997cited by this paper
• Paclitaxel in combination with carboplatin or gemcitabine for the treatment of advanced head and neck cancer.

  1997cited by this paper
• Docetaxel: an active drug for squamous cell carcinoma of the head and neck.

  1996cited by this paper
• Controlling orthopoxvirus infections--200 years after Jenner's revolutionary immunization.

  1996cited by this paper
• A phase II study of ifosfamide in recurrent squamous cell carcinoma of the head and neck.

  1996cited by this paper
• Phase I study of a recombinant adenovirus-mediated gene transfer in lung cancer patients.

  1996cited by this paper
• Carcinoma cell lines become sensitive to DNA-damaging agents by the expression of the adenovirus E1A gene.

  1996cited by this paper
• Expression of E1A in terminally differentiated muscle cells reactivates the cell cycle and suppresses tissue-specific genes by separable mechanisms

  1996cited by this paper
• Evaluation of topotecan in patients with recurrent for metastatic squamous cell carcinoma of the head and neck

  1996cited by this paper
• An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells

  1996cited by this paper
• Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evaluation of clinical response of a phase II-trial.

  1995cited by this paper
• Phase I study of paclitaxel, cisplatin, and ifosfamide in patients with recurrent or metastatic squamous cell cancer of the head and neck.

  1995cited by this paper
• Safety evaluation of Ad5CMV-p53 in vitro and in vivo.

  1995cited by this paper
• Safety Evaluation of Ad5CMY-p53 In Vitro and In Vivo

  1995cited by this paper
• A phase II trial of paclitaxel in squamous cell carcinoma of the head and neck with correlative laboratory studies.

  1995cited by this paper
• Systemic Gene Therapy with p53 Reduces Growth and Metastases of a Malignant Human Breast Cancer in Nude Mice

  1995cited by this paper
• A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group.

  1994cited by this paper
• Oncogenes and cellular-sensitivity to radiotherapy - a study on murine keratinocytes transformed by v-h-ras, v-myc, v-Neu, adenovirus e1a and mutant p53.

  1994cited by this paper
• Docetaxel (Taxotere®): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck

  1994cited by this paper
• A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck

  1994cited by this paper
• Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group.

  1994cited by this paper
• Adenovirus-Mediated Transfer of the CFTR Gene to Lung of Nonhuman Primates: Toxicity Study

  1993cited by this paper
• An adenovirus vector for gene transfer into neurons and glia in the brain

  1993cited by this paper
• Head and Neck Cancer

  1993cited by this paper
• Phase II study of high-dose ifosfamide as a single agent and in combination with cisplatin in the treatment of advanced and/or recurrent squamous cell carcinoma of head and neck.

  1993cited by this paper
• Corrigendum: Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53-mediated repression of transcription (The EMBO Journal(1992)11(3045-3052))

  1992cited by this paper
• Adenoviruses in the immunocompromised host

  1992cited by this paper
• Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53‐mediated repression of transcription.

  1992cited by this paper
• Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study.

  1992cited by this paper
• Newcastle disease virus selectively kills human tumor cells.

  1992cited by this paper
• Adenovirus-mediated transfer of the muscle glycogen phosphorylase gene into hepatocytes confers altered regulation of glycogen metabolism.

  1992cited by this paper
• A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck.

  1992cited by this paper
• Expression of growth-related genes and drug-resistance genes in HTLV-I-positive and HTLV-I-negative post-thymic T-cell malignancies.

  1991cited by this paper
• Chemical modification of an ecotropic murine leukemia virus results in redirection of its target cell specificity.

  1991cited by this paper
• Phase II trial of ifosfamide in recurrent and metastatic head and neck cancer.

  1991cited by this paper
• Prospective randomized trial of high-dose cisplatin and fluorouracil infusion with or without sodium diethyldithiocarbamate in recurrent and/or metastatic squamous cell carcinoma of the head and neck.

  1988cited by this paper
• Immunotherapy of advanced gynecologic cancer patients utilizing mumps virus.

  1988cited by this paper
• Evaluation of High‐Dose Cisplatin and 5‐FU Infusion as Initial Therapy in Advanced Head and Neck Cancer

  1988cited by this paper
• Viral oncolysates in patients with advanced ovarian cancer.

  1988cited by this paper
• p53 and DNA polymerase alpha compete for binding to SV40 T antigen.

  1987cited by this paper
• p53 and DNA polymerase α compete for binding to SV40 T antigen

  1987cited by this paper
• Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection.

  1987cited by this paper
• Cisplatin and 5-FU infusion chemotherapy in advanced, recurrent cancer of the head and neck: an Eastern Cooperative Oncology Group Pilot Study.

  1986cited by this paper
• Improved complete response rate and survival in advanced head and neck cancer after three‐course induction therapy with 120‐hour 5‐FU infusion and cisplatin

  1985cited by this paper
• Analysis of human tonsil and cancer DNAs and RNAs for DNA sequences of group C (serotypes 1, 2, 5, and 6) human adenoviruses.

  1979cited by this paper
• Simultaneous administration of live, enteric-coated adenovirus types 4, 7 and 21 vaccines: safety and immunogenicity.

  1979cited by this paper
• Studies on the use of mumps virus for treatment of human cancer.

  1978cited by this paper
• Adjuvant immunotherapy with BCG in treatment of regional-lymph-node metastases from malignant melanoma.

  1976cited by this paper
• Treatment of human cancer with mumps virus

  1974cited by this paper
• Active immunotherapy with B.C.G. for recurrent malignant melanoma.

  1973cited by this paper
• Augmented immunogenicity of tumor cell homogenates infected with influenza virus.

  1972cited by this paper
• Studies on live mumps virus vaccine. 3. Evaluation of newly developed live mumps virus vaccine.

  1970cited by this paper
• Infections in 18,000 infants and children in a controlled study of respiratory tract disease. I. Adenovirus pathogenicity in relation to serologic type and illness syndrome.

  1969cited by this paper
• Newcastle disease virus as an antineoplastic agent

  1965cited by this paper
• IMMUNOHISTOCHEMICAL STUDIES ON THE INTERACTION BETWEEN EHRLICH ASCITES TUMOR CELLS AND NEWCASTLE DISEASE VIRUS

  1957cited by this paper
• Studies on the use of viruses in the treatment of carcinoma of the cervix

  1956cited by this paper
• Studies on the use of viruses in the treatment of carcinoma of the cervix.

  1956cited by this paper
• Propagation of Newcastle Disease Virus in Ehrlich Ascites Cells In Vitro and In vivo.∗

  1955cited by this paper
• Clinical studies of viruses as antineoplastic agents, with particular reference to egypt 101 virus

  1952cited by this paper
• Note on the experimental use of rabies vaccine for melanomatosis.

  1950cited by this paper

• Current status and perspective of immunotherapy for head and neck squamous cell carcinoma

  2026cites this paper
• Advancements in intratumoral therapies for liver tumors.

  2026cites this paper
• The evolving landscape of oncolytic virus immunotherapy: combinatorial strategies and novel engineering approaches

  2025cites this paper
• A Comprehensive Review of Modern Cancer Therapies Utilizing Oncolytic Viruses

  2025cites this paper
• Novel Treatment Approaches in Recurrent/Metastatic Squamous Head and Neck Cancer.

  2025cites this paper
• Enhancing cancer therapy: the integration of oncolytic virus therapy with diverse treatments

  2024cites this paper
• Emerging strategies in cancer immunotherapy: Expanding horizons and future perspectives

  2024cites this paper
• Intratumoral therapies in head and neck squamous cell carcinoma: A systematic review and future perspectives.

  2024cites this paper
• Review of Safety Data for Adenovirus 5 as a Delivery Vector for Intratumoral Cancer Gene Therapy

  2023cites this paper
• Implications of Gene Therapy in Dentistry and Periodontics: A Narrative Review

  2023cites this paper
• Neoadjuvant use of oncolytic herpes virus G47Δ prevents local recurrence after insufficient resection in tongue cancer models

  2023cites this paper
• Vaccinia (Smallpox) for the Treatment of Ovarian Cancer-Turning an Old Foe Into a Friend?

  2023cites this paper
• Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages

  2023cites this paper
• The impact of oncolytic adenoviral therapy on the therapeutic efficacy of PD-1/PD-L1 blockade.

  2023cites this paper
• Potential Alternative Therapeutic Modalities for Management Head and Neck Squamous Cell Carcinoma: A Review

  2023cites this paper
• The current status of gene therapy in bladder cancer

  2023cites this paper
• Applications of Gene Therapy in Dentistry: A Review Article

  2023cites this paper
• Molecular Targeting of the Most Functionally Complex Gene in Precision Oncology: p53

  2022cites this paper
• Fueling immune checkpoint blockade with oncolytic viruses: Current paradigms and challenges ahead.

  2022cites this paper
• Restoring p53 Function in Head and Neck Squamous Cell Carcinoma to Improve Treatments

  2022cites this paper
• Current status and perspective of tumor immunotherapy for head and neck squamous cell carcinoma

  2022cites this paper
• Oncolytic virus preclinical toxicology studies

  2022cites this paper
• Oncolytic Viruses in Combination Therapeutic Approaches with Epigenetic Modulators: Past, Present, and Future Perspectives

  2021cites this paper
• Nonhuman Primate Adenoviruses of the Human Adenovirus B Species Are Potent and Broadly Acting Oncolytic Vector Candidates

  2021cites this paper
• Combinatorial Approaches for Cancer Treatment Using Oncolytic Viruses: Projecting the Perspectives through Clinical Trials Outcomes

  2021cites this paper
• A Recombinant Human Adenovirus Type 5 (H101) Combined With Chemotherapy for Advanced Gastric Carcinoma: A Retrospective Cohort Study

  2021cites this paper
• Strategies to Develop Potent Oncolytic Viruses and Enhance Their Therapeutic Efficacy.

  2021cites this paper
• Evolving Status of Clinical Immunotherapy with Oncolytic Adenovirus

  2021cites this paper
• Therapeutic strategies of different HPV status in Head and Neck Squamous Cell Carcinoma

  2021cites this paper
• ADME of Biologicals and New Therapeutic Modalities

  2021cites this paper
• Engineering Gene Therapy: Advances and Barriers

  2021cites this paper
• Immunotherapy in Nonmelanoma Skin Cancers

  2020cites this paper
• Gene Therapy in Oncology

  2020cites this paper
• Clinical Application of Oncolytic Viruses: A Systematic Review

  2020cites this paper
• Modeling the spatiotemporal dynamics of virotherapy and immune response as a treatment for cancer

  2019cites this paper
• Optimising intratumoral treatment of head and neck squamous cell carcinoma models with the diterpene ester Tigilanol tiglate

  2019cites this paper
• Bibliometric analysis of oncolytic virus research, 2000 to 2018

  2019cites this paper
• Current Prospects of Molecular Therapeutics in Head and Neck Squamous Cell Carcinoma

  2019cites this paper
• Combination of Cetuximab and Oncolytic Virus Canerpaturev Synergistically Inhibits Human Colorectal Cancer Growth

  2019cites this paper
• Oncolytic Viruses: T-VEC and Others

  2018cites this paper
• Gene Therapy and Free Flaps for Therapeutic Reconstructive Surgery

  2018cites this paper
• Enhancing Oncolytic Adenovirus Vector Efficacy through Co-expression of the p14 Fusion-associated Small Transmembrane Protein and Adenovirus Death Protein

  2018cites this paper
• 3 – Molecular Biology

  2018cites this paper
• Unleashing the Full Potential of Oncolytic Adenoviruses against Cancer by Applying RNA Interference: The Force Awakens

  2018cites this paper
• Oncolytic virotherapy : the story so far

  2017influential citation
• Development of ovarian cancer-targeted adenoviral vectors

  2017cites this paper
• Prospects for combined use of oncolytic viruses and CAR T-cells

  2017influential citation
• Nutritional evaluation of the patients with head and neck squamous cell carcinoma [ Portuguese ]

  2017cites this paper
• Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?

  2017cites this paper
• University of Groningen Ovarian cancer gene therapy

  2017cites this paper
• 2 Resistance to Apoptosis in Cancer Therapy

  2017cites this paper
• Curative effect of HF10 on liver and peritoneal metastasis mediated by host antitumor immunity

  2017cites this paper
• Oncolytic E1B 55KDa-deleted adenovirus replication is independent of p53 levels in cancer cells.

  2017cites this paper
• Important mechanisms of tumorigenesis and their role in chemoresistance of head and neck cancers

  2017cites this paper
• p53 in Head and Neck Squamous Cell Carcinoma

  2017cites this paper
• Oncolytic Immunotherapy for Treatment of Cancer.

  2016cites this paper
• Silk‐elastin‐like protein polymer matrix for intraoperative delivery of an oncolytic vaccinia virus

  2016cites this paper
• Effects of Adenovirus-Mediated Hepatocyte Growth Factor Gene Therapy on Postinfarct Heart Function: Comparison of Single and Repeated Injections

  2016cites this paper
• Viral biotechnology: Production perspective

  2016cites this paper
• Conditionally Replicative Adenoviruses—Clinical Trials

  2016cites this paper
• Oncolytic Viral and Immunotherapy Models Combined with Strategies to Ameliorate Cancer Burden

  2016cites this paper
• Violacein, an indole-derived purple-colored natural pigment produced by Janthinobacterium lividum, inhibits the growth of head and neck carcinoma cell lines both in vitro and in vivo

  2016cites this paper
• Synergistic Cytotoxicity against Human Tumor Cell Lines by Oncolytic Adenovirus dl1520 (ONYX-015) and Melphalan

  2016cites this paper
• Oncolytic adenoviruses targeted to Human Papilloma Virus-positive head and neck squamous cell carcinomas.

  2016cites this paper
• Current Immunotherapeutic Treatments in Colon Cancer

  2016cites this paper
• Surgery of the Salivary Glands

  2016cites this paper
• Les virus oncolytiques, première validation pour une classe thérapeutique pas si nouvelle

  2016cites this paper
• Oncolytic adenoviruses as a therapeutic approach for osteosarcoma: A new hope

  2016cites this paper
• Loss of HLA class I expression in prostate cancer and restoration using adenoviral and adeno-associated viral vectors

  2016cites this paper
• Novel p53 therapies for head and neck cancer

  2016influential citation
• Novel oncolytic viral therapies in patients with thoracic malignancies

  2016cites this paper
• Trial Watch—Oncolytic viruses and cancer therapy

  2016cites this paper
• Radioresistance in head and neck squamous cell carcinoma: Biological bases and therapeutic implications

  2015cites this paper
• Drug coated microneedles for minimally-invasive treatment of oral carcinomas: development and in vitro evaluation

  2015cites this paper
• Genetic Engineering of Oncolytic Viruses for Cancer Therapy

  2015cites this paper
• Cancer vaccines

  2015cites this paper
• From Integrative Omics to Improved Molecular Classification of Head and Neck Cancers

  2015cites this paper
• Novel therapeutic strategies in human malignancy: combining immunotherapy and oncolytic virotherapy

  2015cites this paper
• Transarterial injection of recombinant human type-5 adenovirus H101 in combination with transarterial chemoembolization (TACE) improves overall and progressive-free survival in unresectable hepatocellular carcinoma (HCC)

  2015cites this paper
• Carcinomas of the Head and Neck

  2015cites this paper
• Adenovirus Improves the Efficacy of Adoptive T-cell Therapy by Recruiting Immune Cells to and Promoting Their Activity at the Tumor

  2015cites this paper
• Combination therapy of oncolytic herpes simplex virus HF10 and bevacizumab against experimental model of human breast carcinoma xenograft

  2015cites this paper
• Chapter 15 – Cancer Vaccines

  2015cites this paper
• Polymeric oncolytic adenovirus for cancer gene therapy.

  2015cites this paper
• ONCOLYTIC ADENOVIRUS CODING FOR GM-CSF IN TREATMENT OF CANCER

  2015cites this paper
• Emerging drugs for head and neck cancer

  2015cites this paper
• Exploring the Oncolytic Potentail of a Double Knock-Out Tanapoxvirus Containing FLiC Transgene

  2015cites this paper
• Targeted Therapy in Solid Tumors: Head and Neck

  2015cites this paper
• Head and neck cancers: Incidence, Epidemiological Risk, and Treatment Options

  2015cites this paper
• Nucleic Acid Targeting: Towards Personalized Therapy for Head and Neck Cancer

  2015cites this paper
• Combining oncolytic virotherapy and cytotoxic therapies to fight cancer.

  2014cites this paper
• Gene therapy for malignant glioma

  2014cites this paper
• Serotype chimeric oncolytic adenovirus coding for GM‐CSF for treatment of sarcoma in rodents and humans

  2014cites this paper
• Themutational spectrum of squamous-cell carcinoma of the head and neck : targetable genetic events and clinical impact

  2014cites this paper
• Dual Disruption of DNA Repair and Telomere Maintenance for the Treatment of Head and Neck Cancer

  2014cites this paper
• Immunotherapeutic Potential of Oncolytic Vaccinia Virus

  2014cites this paper
• Cancer Therapy : Preclinical Dual Disruption of DNA Repair and Telomere Maintenance for the Treatment of Head and Neck Cancer

  2014cites this paper
• Terapia génica para el tratamiento del cáncer

  2014cites this paper
• Beta-2-microglobulin gene transfer in hla class i deficient tumor cells using recombinant adenovirus

  2014cites this paper
• The use of oncolytic viruses in selected tumours

  2014cites this paper